The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

Stop the progression of coronary plaque buildup

Something’s Fishy

Heart disease patients with high LDL levels stopped the
progression of coronary plaque buildup by using the
cholesterol-lowering statin drug Lipitor, according to a study
that made headlines and was featured on recent national
television news broadcasts. Another group of patients in the
study took the statin drug Pravachol; in these subjects, plaque
buildup continued to progress.

This research was widely reported for two reasons: 1) Lipitor
outperformed its rival Pravachol in lowering LDL, and 2) Lipitor was shown to stop the progression of coronary plaque aggregation.

Sounds like a pretty clear win for Lipitor, doesn’t it? Well
if you’re not looking too closely it does. Because between the perception and the reality of this study there’s a train wreck of misconceptions. And what’s worse, one of the most sweeping comments about the study provides some medical advice that could border on being downright dangerous.

Nothing up my sleeve

The Associated Press and several other major news outlets
portrayed this study as the first time two different statin
drugs have been tested against each other, “head-to-head.”

The Cleveland Clinic directed the research of more than 500
coronary heart disease (CHD) patients over a period of 18
months. Results of the study were announced at a meeting of the American Heart Association, and a full report has been submitted for publication. So for now we can only rely on media reports which, when read carefully, supply these two important pieces of information:

  • Pfizer, the maker of Lipitor, provided sponsorship of thestudy (according to the New York Times).
  • Patients in the Lipitor group received 80 mg of the drug.
  • Patients in the Pravachol group received 40 mg of that drug.

If you tried stacking the deck like that in Vegas they’d run you
out of town on a rail.

Holes you could drive a truck through

Here’s the lead sentence of the Pfizer press release about the study: “Patients taking Pfizer Inc’s cholesterol-lowering
medicine Lipitor (atorvastatin calcium) experienced a
significant reduction in the progression of atherosclerosis, or
hardening of the arteries, compared to patients who received Pravachol (pravastatin) “

Many print and television reporters simply picked up their
information from that press release and faithfully reported the
“results.” But kudos to the Health Day News reporter who did
some digging and interviewing and discovered that the study was specifically designed to produce two different outcomes so that the changing LDL levels of each group could be compared to changes (or lack of change) in arterial plaque. So the trial was not a “head-to-head” statin showdown at all. Any third-grader can tell you that 80-on-40 is not a level playing field.

Furthermore, the fact that Lipitor reduced plaque by 0.4 percentover a year and a half may not actually have any significance at all in terms of preventing deaths from CHD. Until long-term studies on mortality can be mounted, this slight plaque reduction is little more than a moot point.

Statins have also been shown to produce unhealthy side effects, such as liver and kidney dysfunction (according to Pfizer’s Lipitor web site). So when the study is eventually published, I hope we’ll see a genuinely comprehensive comparison of the side effects from taking high doses of Lipitor against low doses of Pravachol.

But don’t hold your breath.
Sinking to a new low

The lead author of the study, Dr. Steven Nissen (a cardiologist at the Cleveland Clinic) added a comment that reopens the debate over the proper level of LDL, the supposedly “bad” cholesterol.

Dr. Nissen told the Associated Press that the data seem to show that “There is no such thing as too low an LDL.” MSNBC picked upon that comment and ran this sub-head on the MSNBC web site:
“New research indicates the lower the level of LDL the better.”

But prior research doesn’t support that claim. And that’s
putting it mildly. Because when LDL is too low, the risk of
death may actually increase.

I asked HSI Panelist Allan Spreen, M.D., to comment on this idea that “the lower the LDL the better” and he pointed out this revealing result of the watershed Framingham Heart Study: “The largest, longest, and most prestigious heart disease study (Framingham) showed that total cholesterol levels (‘total,’ now, mind you, they didn’t talk a whole lot about LDL) that went below 160 caused heart disease problems to go back up! So it’s a curve that bottoms out at 160 instead of a line that gets better and better as you get lower and lower.”

Dr. Spreen’s statement is confirmed by an article in Red Flags Weekly by Malcolm Kendrick, M.D., which offers this quote about the Framingham results as published in the Journal of the American Medical Association: “There is a direct association between falling cholesterol levels over the first 14 years and mortality over the following 18 years.”

And from the National Heart, Lung and Blood Institute’s Honolulu Heart Program (an ongoing study that began in 1965 with more than 8,000 men), Dr. Kendrick presents this quote as it appeared in the Lancet medical journal: “Our data accord with previous findings of increased mortality in elderly people with low serum cholesterol, and show that long-term persistence of low cholesterol concentration actually increases the risk of death.”

No such thing as too low?

The lower the better?

It’s a shame that many heart patients will read about this study and take the lazy reporting of the mainstream news outlets at face value.

To Your Good Health,

Jenny Thompson
Health Sciences Institute

Sources:
“Pfizer’s Lipitor Shown to Stop Progression of Plaque Build-Up in Arteries, New Study Shows” Pfizer News Release, 11/12/03, pfizer.com

“How Low Should Bad Cholesterol Go? New research indicates the lower the level of LDL the better” Associated Press, 11/12/03, msnbc.com

“Study Finds Differences in 2 Cholesterol-Lowering Drugs” Gina Kolata, The New York Times, 11/12/03, nytimes.com

“Doctors Divided Over Cholesterol Drugs Study” Health Day News, 11/13/03, ajc.com

“The Cholesterol-Lowering Drugs Olympics” Nicholas Regush, Red Flags Daily, 11/15/03, redflagsdaily.com

“Why the Cholesterol-Heart Disease Theory is Wrong” Malcolm Kendrick, M.D., Red Flags Weekly, 12/12/02, redflagsweekly.com

“Lipitor Prescribing Information” lipitor.com

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at hsionline.com (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 

ARBITRATION IS MANDATORY AND THE EXCLUSIVE REMEDY FOR ANY AND ALL DISPUTES RELATED TO THIS WEBSITE, THIS AGREEMENT, AND ANY TELEPHONE CALLS, EMAILS, OR TEXT MESSAGES THAT YOU RECEIVE FROM OR ON BEHALF OF US, UNLESS SPECIFIED BELOW OR UNLESS YOU OPT-OUT.

Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or help@hsionline.com. Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at help@hsionline.com or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at help@hsionline.com.

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at help@hsionline.com.